口服芬戈莫德治疗慢性炎性脱髓鞘性多发性神经根神经病(FORCIDP试验):一项双盲、多中心、随机对照试验
FORCIDP试验在48个神经中心纳入106例正在接受IVIg或糖皮质激素治疗的CIDP患者,随机接受芬戈莫德0.5mg每日一次或安慰剂。因中期分析时44例确认恶化事件达到无效标准而终止。芬戈莫德组无确认恶化生存估计42%(95%CI 23-60)与安慰剂组43%(28-59)无显著差异(p=0.91)。
要点
- 芬戈莫德0.5mg每日一次在CIDP治疗中未优于安慰剂。
- 芬戈莫德组无确认恶化生存估计42%,安慰剂组43%,p=0.91。
- 芬戈莫德组严重不良事件9例(17%),安慰剂组4例(8%)。
核心结论
- 芬戈莫德0.5mg每日一次治疗CIDP未优于安慰剂。
- 未来试验设计应考虑突然停用IVIg后部分患者可能很快复发而另一些患者仍保持缓解的可能性。
研究设计与样本
- 双盲、多中心、随机、安慰剂对照、平行组、事件驱动研究,在澳大利亚、加拿大、以色列、日本、美国和欧洲九国的48个神经中心进行。
- 106例接受IVIg或糖皮质激素的CIDP患者按1:1随机分配至每日一次口服芬戈莫德0.5mg或安慰剂,按INCAT残疾量表评分分层。
- 治疗时长灵活,最长可达4.5年;随机化后糖皮质激素在8周内逐渐减停,既往IVIg在首剂研究药物前一天最后一剂后停用。
- 主要终点为至首次确认恶化(校正INCAT残疾量表评分较基线增加≥1分)的时间,在全分析集中评估。
主要发现
- 2013年1月24日至2016年3月10日随机分配106例:芬戈莫德组54例(41例既往用IVIg、13例用糖皮质激素),安慰剂组52例(41例既往用IVIg、11例用糖皮质激素)。
- 中期分析时44例确认恶化事件发生后,独立数据监查委员会建议因无效终止试验。
- 研究结束时无确认恶化生存估计:芬戈莫德组42%(95%CI 23-60) vs 安慰剂组43%(28-59),p=0.91,无显著差异。
- 不良事件:芬戈莫德组41例(76%) vs 安慰剂组44例(85%);严重不良事件:芬戈莫德组9例(17%) vs 安慰剂组4例(8%)。
- 芬戈莫德组最常见不良事件为头痛12例(22%)、高血压10例(19%)、肢体疼痛7例(13%);导致研究终止的不良事件芬戈莫德组7例(13%),安慰剂组0例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验因无效提前终止。
- 原文指出未来试验设计应考虑突然停用IVIg后部分患者可能很快复发而另一些患者仍保持缓解的可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fingolimod is approved for the treatment of relapsing-remitting multiple sclerosis and was effective in experimental autoimmune neuritis in rats, a possible model for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We aimed to evaluate the efficacy of fingolimod in delaying disability progression in patients with CIDP who withdrew from currently effective treatments (intravenous immunoglobulin [IVIg] or corticosteroids). METHODS: This double-blind, multicentre, randomised, placebo-controlled, parallel-group, event-driven study was done at 48 neurology centres in Australia, Canada, Israel, Japan, the USA, and nine countries in Europe. Participants with CIDP who were receiving IVIg or corticosteroids were randomly assigned (1:1) to once-daily oral fingolimod 0·5 mg or placebo. Owing to the event-driven design, treatment duration was flexible and could be up to 4·5 years. Randomisation was done with an automated interactive voice response-web response system and was stratified by Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale scores. Previous IVIg treatment was discontinued after one final course ending the day before the first dose of fingolimod or placebo was given, whereas corticosteroids were tapered off over 8 weeks after randomisation. The primary endpoint was time to first confirmed worsening (≥1 point increase on the adjusted INCAT disability scale score versus baseline) and was assessed in the full analysis set, which consisted of all patients who underwent randomisation and had at least one efficacy assessment for the primary analysis. The survival distribution functions of time to first worsening were estimated within each treatment group according to the Kaplan-Meier survival distribution function and compared with a stratified log-rank test. The trial is registered with ClinicalTrials.gov, number NCT01625182. FINDINGS: Of 106 participants randomly assigned between Jan 24, 2013, and March 10, 2016, 54 received fingolimod (41 who had been receiving IVIg and 13 who had been receiving corticosteroids) and 52 received placebo (41 who had been receiving IVIg and 11 who had been receiving corticosteroids). The trial ended for futility as recommended by an independent data monitoring committee after an interim analysis when 44 confirmed worsening events had occurred. At the end of the study, the survival estimate of the proportion of participants free from confirmed worsening was not significantly different between the fingolimod group (42%, 95% CI 23-60) and the placebo group (43%, 28-59; p=0·91). Adverse events occurred in 41 (76%) participants receiving fingolimod and 44 (85%) on placebo, and serious adverse events occurred in nine (17%) and four (8%) patients, respectively. The most common adverse events with fingolimod were headache (12 [22%] patients), hypertension (ten [19%]), and extremity pain (seven [13%]). Adverse events leading to study discontinuation occurred in seven (13%) participants on fingolimod and none on placebo. INTERPRETATION: Fingolimod 0·5 mg once-daily was not better than placebo for the treatment of CIDP. Future trial designs should take account of the possibility that if IVIg is stopped abruptly, some patients might relapse soon afterwards whereas others might remain in remission. FUNDING: Novartis Pharma.
引用
- Hughes R, Dalakas MC, Merkies I, et al. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurol. 2018. PMID: 30001923. doi:10.1016/S1474-4422(18)30202-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。